Ra Pharmctl Inc (NASDAQ:RARX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus target price of $27.67 for the company and are forecasting that the company will post ($0.44) EPS for the current quarter, according to Zacks. Zacks has also assigned Ra Pharmctl an industry rank of 68 out of 265 based on the ratings given to its competitors.

Several research analysts have commented on RARX shares. Jefferies Group started coverage on shares of Ra Pharmctl in a research report on Monday, November 21st. They set a “buy” rating and a $25.00 price objective for the company. SunTrust Banks, Inc. started coverage on shares of Ra Pharmctl in a research report on Monday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. BMO Capital Markets started coverage on shares of Ra Pharmctl in a research report on Monday, November 21st. They set an “outperform” rating and a $26.00 price objective for the company. Finally, Credit Suisse Group started coverage on shares of Ra Pharmctl in a research report on Monday, November 21st. They set an “outperform” rating and a $19.00 price objective for the company.

COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Ra Pharmctl Inc (RARX) to Post ($0.44) Earnings Per Share” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be read at http://www.watchlistnews.com/brokerages-anticipate-ra-pharmctl-inc-rarx-to-post-0-44-earnings-per-share/1061137.html.

In related news, major shareholder Harry R. Weller purchased 338,462 shares of the stock in a transaction dated Monday, October 31st. The stock was bought at an average cost of $13.00 per share, for a total transaction of $4,400,006.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rajeev M. Shah purchased 161,538 shares of the stock in a transaction dated Monday, October 31st. The shares were bought at an average price of $13.00 per share, with a total value of $2,099,994.00. The disclosure for this purchase can be found here.

Ra Pharmctl (NASDAQ:RARX) opened at 15.38 on Monday. The company’s market capitalization is $346.76 million. Ra Pharmctl has a 52-week low of $12.05 and a 52-week high of $16.56. The stock has a 50 day moving average price of $14.02 and a 200 day moving average price of $13.74.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

5 Day Chart for NASDAQ:RARX

Get a free copy of the Zacks research report on Ra Pharmctl (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.